The Centers for Disease Control and Prevention estimate for human infectious diseases caused by bacteria with a biofilm phenotype is 65 percent and the National Institutes of Health estimate is closer to 80 percent. Biofilms are hostile microbial aggregates because, within their polymeric matrix cocoons, they are protected from antimicrobial therapy and attack from host defenses. Biofilm-infected wounds, even when closed, show functional deficits such as deficient extracellular matrix and impaired barrier function, which are likely to cause wound recidivism. The management of invasive wound infection often includes systemic antimicrobial therapy in combination with débridement of wounds to a healthy tissue bed as determined by the surgeon who has no way of visualizing the biofilm. The exceedingly high incidence of false-negative cultures for bacteria in a biofilm state leads to missed diagnoses of wound infection. The use of topical and parenteral antimicrobial therapy without wound débridement have had limited impact on decreasing biofilm infection, which remains a major problem in wound care. Current claims to manage wound bio-film infection rest on limited early-stage data. In most cases, such data originate from limited experimental systems that lack host immune defense. In making decisions on the choice of commercial products to manage wound biofilm infection, it is important to critically appreciate the mechanism of action and significance of the relevant experimental system. In this work, the authors critically review different categories of antibiofilm products, with emphasis on their strengths and limitations as evident from the published literature.
After viewing this course, the participant should be able to:
- Understand the basics of biofilm infection and be able to distinguish between planktonic and biofilm modes of growth.
- Have a working knowledge of conventional and emerging antibiofilm therapies and their modes of action as they pertain to wound care.
- Understand the challenges associated with testing and marketing antibiofilm strategies and the context within which these strategies may have effective value.
Chandan K. Sen, Ph.D.; Sashwati Roy, Ph.D.; Shomita S. Mathew-Steiner, Ph.D.; Gayle M. Gordillo, M.D.
Plastic and Reconstruction Surgery®Editors: Editor-in-Chief: Rod J. Rohrich, MD
Co-Editor: James M. Stuzin, MD
Section Editors: Donald H. Lalonde, MD; John YS Kim, MD
AMA PRA Category 1 CreditTM: 1.0
Patient Safety Credit: 0.5
Media:Journal Article, video
Release Date: 08/01/2021
Expiration Date: 08/01/2024
Estimated time to complete this course: 1 hour
*Course access ends on course expiration date
Directly provided by the American Society of Plastic Surgeons® (ASPS®)
The American Society of Plastic Surgeons (ASPS) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The ASPS designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is intended for plastic surgery practitioners, residents, and other healthcare professionals interested in translating expanded knowledge into practice for the improvement of patient outcomes in plastic and reconstructive surgery.Disclosures
Link to Current Disclosures
Return Policy for Downloaded and Viewable Products
Products which are downloaded or viewable after purchase may not be returned. By placing an order you are agreeing to the product return terms and conditions set forth by this site. ASPS Shop Return Policy
Product Code: 31735